Results 81 to 90 of about 30,153 (204)

Performance comparison between multiple prediction strategies, for prediction of aromatase inhibitor non-response.

, 2019
Performance comparison between multiple prediction strategies, for prediction of aromatase inhibitor non-response.
Adrian V. Lee (600737), Matthew Ruffalo (838910), Ziv Bar-Joseph (19139), Jian Chen (15340), Roby Thomas (6320717), Steffi Oesterreich (109122)   +5 more
core   +1 more source

Effect of anastrozole on bone mineral density and lipid profiles when used to prevent breast cancer in high risk postmenopausal women

, 2012
PhDThe role of aromatase inhibitors (AIs) in breast cancer has expanded since their introduction in the mid-1990s. They are superior to tamoxifen in the treatment of postmenopausal women with oestrogen dependant tumours in the metastatic, neoadjuvant ...
Singh, Shalini
core  

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.

, 2011
Bone mineral density (BMD)-based guidelines for bone-directed therapy in women with early breast cancer (EBC) appear inadequate for averting fractures, particularly during aromatase inhibitor (AI) therapy.
Hadji, P., Lipton, Allan, Lipton, A., Aapro, M. S., Coleman, R. E., Guise, T., N.J. Bundred, Gnant, M., P. Hadji, Bundred, N. J., T. Guise, Bundred, N J, Body, J. J., Brufsky, A., M.S. Aapro, M. Gnant, Brufsky, Adam, R.E. Coleman, Hadji, Peyman, Aapro, M.S., J.J. Body, A. Brufsky, Coleman, Rosemary, Gnant, Michael, Guise, Theresa, A. Lipton, Body, Jean-Jacques   +26 more
core   +1 more source

Comparison of Recurrence Rates in Patients with Locally Advanced Breast Cancer after Mastectomy and Received Aromatase Inhibitor Therapy with Steroids and Nonsteroids

, 2021
Introduction. Breast cancer is a problem that is still faced throughout the world. The incidence of cancer in Indonesia is at number 8 in Southeast Asia. The incidence of breast cancer in women is 42.1 per 100,000 population.
Iskandar Ali, Yante, I Ketut, Desak Gede Agung Suprabawati   +2 more
core   +1 more source

Management of adenomyosis in infertile women: comparison between laparotomic resection and administration of aromatase inhibitor (Experience in 55 cases)

, 2006
The objective of this study was to observe the results of adenomyosis mangement with resection and administration of aromatase inhibitor. Cases of ademyosis in infertile women were collected for three years (January 1999 to December 2001) and the ...
Rajuddin, Rajuddin, Jacoeb, T. Z.
core   +1 more source

Epiretinal membrane formation associated with letrozole therapy – Two case reports

Indian Journal of Ophthalmology. Case Reports
Letrozole, an aromatase inhibitor, is being increasingly used for adjuvant endocrine therapy in hormone-positive postmenopausal breast cancer. Although aromatase inhibitors are thought to increase vitreoretinal traction by causing estrogen reduction ...
Hridya Hareendran, R Unnikrishnan Nair, Manoj Soman, Varsha Vijayan   +3 more
doaj   +1 more source

First dual aromatase-steroid sulfatase inhibitors

, 2003
Aromatase inhibitors in clinical use block the biosynthesis of estrogens. Hydrolysis of estrone 3-sulfate by steroid sulfatase is an important additional source of tumor estrogen, and blockade of both enzymes should provide a more effective endocrine ...
Chander, S.K., Purohit, A., Bubert, C., Potter, B.V.L., Reed, M.J., Sutcliffe, O.B., Woo, L.W.L., Grasso, A.   +7 more
core   +1 more source

Capivasertib After Progression on CDK4/6 Inhibitor Combined with Endocrine Therapy in a Patient with HR-Positive, HER2-Negative Metastatic Breast Cancer: A Case Report

healthbook TIMES. Oncology Hematology
Capivasertib, an AKT inhibitor, combined with fulvestrant, has demonstrated significantly improved progression-free survival compared with fulvestrant alone in patients with hormone receptor (HR)-positive advanced breast cancer whose disease progressed ...
Diana Chiru, Marcus Vetter
doaj   +1 more source

Comparing exercise responses to aerobic plus resistance training between postmenopausal breast cancer survivors undergoing aromatase inhibitor therapy and healthy women

, 2018
Background: The aim of this study was to explore whether postmenopausal breast cancer survivors undergoing aromatase inhibitor therapy differ from healthy postmenopausal women in their response to the same aerobic + resistance training.
Freitas Junior, Ismael F., Codogno, Jamile S., Ana Carolina A. C. Trindade, Rossi, Fabricio E., Trindade, Ana Carolina A. C., Juliana Viezel, Fabricio E. Rossi, Ismael F. Freitas Junior, Winters-Stone, Kerri M., Aro, Bruna L., Viezel, Juliana, Thais R. S. de Paulo, Bruna L. Aro, Jamile S. Codogno, Kerri M. Winters-Stone, Paulo, Thais R. S. de   +15 more
core   +1 more source

Central Precocious Puberty as a Complication of Therapy with Adrenocorticotropin (ACTH) and an Aromatase Inhibitor for Refractory Nephrotic Syndrome

Case Reports in Pediatrics, 2019
Glucocorticoids are typically prescribed for the treatment of idiopathic nephrotic syndrome of childhood. In selected patients with refractory focal segmental glomuerulosclerosis (FSGS), adrenocorticotropin (ACTH) can be used to induce remission and ...
Sungeeta Agrawal, Robert Gensure, Lawrence Milner, Julie Nicoletta, Abdollah Sadeghi-Nejad   +4 more
doaj   +1 more source